Meta-Analysis: Tirzepatide Produces 16.5% Weight Loss in Non-Diabetic Obese Adults With a Clear Dose-Response Pattern | Research

The takeaway

A meta-analysis of 4 RCTs (3,553 participants) found tirzepatide produced an average 16.5% body weight reduction in non-diabetic obese adults, with each additional 1 mg dose adding 0.72% more weight loss, and serious adverse events were no higher than placebo.

16.5% average weight loss
Non-diabetic obese adults on tirzepatide lost an average of 16.5% of their body weight — with 23 times higher odds of achieving ≥15% weight loss compared to placebo — approaching results previously only seen with bariatric surgery.

What the researchers found

Pooled analysis of 4 RCTs (n=3,553) demonstrated:

- Mean body weight reduction: -16.54% vs. placebo (95% CI: -17.48 to -15.59; p<0.00001)

- Clear dose-response: each 1 mg increase in tirzepatide added -0.72% more weight loss (meta-regression p=0.0014)

- Achievement of ≥15% weight loss: OR 23.25 (95% CI: 18.06-29.94)

- BMI reduction: -7.09 kg/m²

- Waist circumference reduction: -12.77 cm

- HbA1c improvement: -0.42%

- Quality of life improved (SF-36v2 and IWQOL-Lite-CT scores)

Safety: Nausea (OR 4.20), vomiting (OR 6.93), and diarrhea (OR 3.80) were more common, but serious adverse events were comparable to placebo (OR 0.97).

Why it matters

Obesity affects over 40% of American adults and drives type 2 diabetes, heart disease, and numerous other conditions. Tirzepatide's 16.5% average weight loss approaches what was previously only achievable through bariatric surgery. This meta-analysis quantifies the dose-response relationship for the first time, helping clinicians optimize dosing, and confirms that despite GI side effects, serious adverse events are no more common than placebo — a critical finding for a medication intended for long-term use.

How the study worked

Systematic review and meta-analysis of RCTs. PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched (January 2020 to April 2025). Inclusion criteria: tirzepatide (5-15 mg or MTD) vs. placebo, minimum 52 weeks, non-diabetic obese adults. Data pooled using fixed- or random-effects models. Dose-response meta-regression performed. Sensitivity analyses confirmed reliability.

What this study cannot tell us

Only 4 RCTs met inclusion criteria, limiting the statistical power for subgroup analyses. All trials had at least 52 weeks duration, but longer-term data on weight regain after discontinuation are limited. The meta-analysis focused on non-diabetic adults, so results may not apply to people with type 2 diabetes. Gastrointestinal side effects were significantly higher, which could affect real-world adherence. The analysis did not separate effects by sex, age, or baseline BMI.

How to read the evidence

This is a systematic review and meta-analysis of 4 randomized controlled trials — representing the highest level of evidence. The consistent results (I² not reported as high), clear dose-response relationship (confirmed by meta-regression), and sensitivity analyses strengthen confidence in the findings. However, the limited number of trials is a constraint.

When this study was published

Published in 2025 with data through April 2025, this is one of the most current meta-analyses on tirzepatide for weight loss in non-diabetic populations, capturing the latest SURMOUNT trial data.

The bigger picture

Tirzepatide's dual GIP/GLP-1 mechanism produces greater weight loss than single GLP-1 agonists like semaglutide. This meta-analysis establishes the dose-response curve and confirms the safety profile, providing essential data as the field moves toward personalized obesity treatment. With tirzepatide now FDA-approved for both diabetes (Mounjaro) and obesity (Zepbound), understanding the optimal dose for individual patients is critical for maximizing benefit while managing side effects.

Questions still open

What is the optimal tirzepatide dose that maximizes weight loss while minimizing gastrointestinal side effects for individual patients?
How much weight is regained after stopping tirzepatide, and what strategies can maintain weight loss long-term?
Does the dose-response relationship plateau at higher doses, or would doses above 15 mg produce even greater weight loss?

Common questions

How much weight can you lose on tirzepatide (Zepbound)?

According to this meta-analysis of 4 clinical trials with over 3,500 non-diabetic obese participants, the average weight loss on tirzepatide was 16.5% of body weight. For a 250-pound person, that would be about 41 pounds. Higher doses produce more weight loss — each additional 1 mg adds about 0.72% more weight loss. Participants on tirzepatide were 23 times more likely to lose at least 15% of their body weight compared to placebo.

Is tirzepatide safe for long-term weight loss?

This meta-analysis found that while gastrointestinal side effects (nausea, vomiting, diarrhea) are significantly more common on tirzepatide, serious adverse events were no different from placebo (OR 0.97). This means the drug causes uncomfortable but manageable side effects — mostly GI-related — without increasing the risk of dangerous medical complications. The studies included in this analysis lasted at least one year, supporting its use for long-term weight management.

Read the original research

Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Cureus, 17(6), e85531

View on PubMed ↗Publisher’s paper ↗

Citation

Kasagga, Alousious; Assefa, Amanuel Kefyalew; Amin, Maysaa N; Hashish, Rahma; Agha Tabari, Khaled; Swami, Shivling S; Nakasagga, Kevin. (2025). Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. Cureus, 17(6), e85531. https://doi.org/10.7759/cureus.85531